• Explore /
  • Poster
  • / MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.

MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.

Abstract Poster

Authors

null

Paul G. Richardson

Dana-Farber Cancer Institute, Boston, MA

Paul G. Richardson , Craig Hofmeister , Noopur S. Raje , David Samuel DiCapua Siegel , Sagar Lonial , Jacob Laubach , Yvonne Adeduni Efebera , David H. Vesole , Ajay K. Nooka , Jacalyn Rosenblatt , Mohamed H. Zaki , Ye Hua , Yan Li , Sheetal Shah , Jianming Wang , Kenneth Carl Anderson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01497093

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8589)

DOI

10.1200/jco.2014.32.15_suppl.8589

Abstract #

8589

Poster Bd #

276

Abstract Disclosures

Similar Posters

First Author: Paul Gerard Guy Richardson

First Author: James D. Hilger

First Author: Cyrille Touzeau

First Author: Cristina Gasparetto